IceCure Medical Ltd. (NASDAQ:ICCM) stock fell more than 10% during Friday’s session.
On Thursday, the company said it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement, removing the listing deficiency related to its share price.
This compliance was confirmed after the stock maintained a closing bid price of $1.00 or greater for ten consecutive business days from June 4 to June 17, 2026, which has now closed the bid price deficiency matter with Nasdaq.
IceCure Medical (ICCM) Business Overview And ProSense System
IceCure Medical develops and markets liquid nitrogen-based cryoablation systems that destroy benign and cancerous tumors by freezing them.
